Straits Times Index
3,274.81 -25.23 (-0.76%) Nikkei
38,303.39 -531.71 (-1.37%) Hang Seng
18,556.25 +76.88 (+0.42%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,767.04 -915.00 (-1.44%) CMC Crypto 200
1,301.13 -64.00 (-4.69%)
BNTX Jan 2025 210.000 call
| Previous close | 0.5700 |
| Open | 0.5600 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 210.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5500 - 0.5700 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Insider MonkeyBioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to BioNTech’s First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria […]
BenzingaWhat's Going With BioNTech Stock On Monday?
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine maker reported sales of 187.6 million euros (roughly $202 million), down from 1.3 billion euros reported a year ago, missing the consensus of 427.5 million euros. The European biotech firm posted a quarterly net loss of 315 million euros, compared with a profit of 502 million a year earlier. “We expect t
